Mayzent

Siponimod, the active ingredient in Mayzent, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as a 2 mg oral tablet for oral use. It is indicated for relapsing forms of multiple sclerosis, including secondary progressive disease with active inflammation, and works by modulating immune cell trafficking.

GNH USA supplies Mayzent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this disease‑modifying therapy.

Mayzent (siponimod) is used within the multiple sclerosis disease family to modify disease activity and reduce relapses.

- Relapsing‑remitting multiple sclerosis: reduces annualized relapse rate and slows disability progression. - Secondary progressive multiple sclerosis with active disease: decreases inflammatory activity and delays further disability accumulation.

Siponimod may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Hypertension: increased blood pressure readings. - Elevated liver enzymes: transient ALT/AST elevations. - Lymphopenia: reduced peripheral lymphocyte count. - Nasopharyngitis: upper respiratory tract infection symptoms. - Diarrhea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe infections: opportunistic or serious bacterial infections. - Macular edema: visual disturbances requiring ophthalmologic assessment. - Cardiac conduction abnormalities: bradyarrhythmias or AV block. - Severe liver injury: hepatitis or hepatic failure.

Before initiating Mayzent, several safety considerations should be addressed.

- Baseline assessment: obtain complete blood count and liver function tests prior to therapy. - Infection risk: monitor for signs of infection and defer treatment during active infections. - Vaccination: avoid live vaccines while receiving siponimod. - Pregnancy: contraindicated in pregnancy; use effective contraception. - Drug interactions: review concomitant medications, especially CYP2C9 substrates and inhibitors. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Siponimod can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase siponimod exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower siponimod levels and reduce effectiveness.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may exacerbate bradycardia during treatment initiation. - Live vaccines: timing adjustments needed to prevent reduced vaccine efficacy. - Antiplatelet or anticoagulant therapy: monitor for increased bleeding risk.